Seres Therapeutics, Inc. (MCRB): Total Liabilities
$93.97M
As of 2025-12-31
$67.05M
As of 2026-06-30
-34.7%
3-year compound annual growth
-11.0%
5-year compound annual growth
+23.4%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.97M | -25.4% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $126.03M | -68.8% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $403.46M | +19.4% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $338.00M | +51.3% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $223.35M | +32.8% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $168.19M | -7.0% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $180.76M | +7.3% | 2021-03-02, Balance as of period end |
| 2018-12-31 | $168.52M | +30.8% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $128.82M | -8.0% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $140.01M | n/m | 2018-03-08, Balance as of period end |
| 2015-12-31 | $11.51M | +44.0% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $7.99M | n/a | 2016-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $93.97M | -25.4% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $39.41M | -8.1% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $2.89M | -45.0% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $69.14M | +0.8% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $67.76M | +138.5% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $53.41M | +25.5% |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $17.20M | -13.1% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $9.73M | -42.2% |
Compare MCRB, ELTP, MNPR, PRLD side by side · Screen every company in Pharmaceutical Preparations ↗